title: Antinuclear antibodies and anticytoplasmic antibodies in bronchial asthma.
abstract: The presence of antinuclear antibodies and anticytoplasmic antibodies was evaluated in the sera of 50 patients with bronchial asthma and 35 matched control subjects with miscellaneous medical diseases with the use of an indirect immunofluorescent assay with HEp-2 cells as substrate. The results were compared to age, sex, atopic status, dose, and duration of the antiasthmatic medication, immunotherapy, severity of the disease, and presence or absence of myalgia. The patients had mild to moderate asthma. The incidence of fluorescent anticytoplasmic antibodies (FACA) in the sera of patients with asthma was statistically significant (p = 0.02) in comparison to FACA in the sera of the control subjects. The combined incidence of fluorescent antinuclear antibodies (FANA) and FACA was found to be significantly higher among atopic subjects with asthma (p = 0.03) and the subjects with asthma and with myalgia (p less than 0.05). The 20% incidence of FACA in this group of subjects with asthma was significantly greater (p less than 0.0001) than the reported 2.7% incidence of FACA in a group of patients with various rheumatologic diseases. Variables, such as dose and duration of antiasthma medications and immunotherapy did not appear to influence the presence of FANA and FACA in their sera. The significance of positive FANA and FACA in this group of subjects with asthma is not known and needs to be evaluated by long-term studies.
authors.affiliation: Department of Pediatrics, Louisiana State University Medical Center, Shreveport 71130-3932.
authors.forename: P
authors.initials: P
authors.lastname: Menon
authors.forename: V
authors.initials: V
authors.lastname: Menon
authors.forename: B C
authors.initials: BC
authors.lastname: Hilman
authors.forename: R
authors.initials: R
authors.lastname: Wolf
authors.forename: L
authors.initials: L
authors.lastname: Bairnsfather
mesh_terms: D000906:Antibodies / Q000032:analysis*; D000974:Antibodies, Antinuclear / Q000032:analysis*; D001249:Asthma / Q000150:complications / Q000276:immunology* / Q000503:physiopathology; D003593:Cytoplasm / Q000276:immunology*; D005455:Fluorescent Antibody Technique; D006801:Humans; D006967:Hypersensitivity / Q000150:complications / Q000276:immunology; D009135:Muscular Diseases / Q000276:immunology; D012216:Rheumatic Diseases / Q000276:immunology
chemical_list: D000906:Antibodies; D000974:Antibodies, Antinuclear